Vol. 49 | 2026.07.13 — 07.19 | Market Mood: 78 / 100 — Optimistic
Precision medicine accelerates, fueled by converging AI and advanced biologics. This week validates AI’s clinical impact, with 2 drug candidates entering human trials. Cell and gene therapies, including CAR T and iPSC therapies, broaden indications beyond oncology, evidenced by 165 RMAT designations. Decentralized diagnostics, POCT and wearables, are rapidly proliferating.
- Biologics CDMO investment exceeds $4B USD.
Western R&D directors and tech investors must strategically integrate AI, optimize biomanufacturing, and prioritize patient-centric solutions. This week’s data is crucial for competitive advantage and addressing unmet medical needs.
This infographic lets you judge at a glance whether the Full Intelligence Report is worth reading.
If the infographic makes you want to read the full report, please click the download button below.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments